CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0476 (clinicaltrials.gov NCT No: NCT00960492)
Title:A Phase 1 Dose Finding Study of the Safety and Pharmacokinetics of XL184 Administered Orally in Combination with Temozolomide and Radiation Therapy in the First Line Treatment of Subjects with Malignant Gliomas
Principal Investigator:John DeGroot
Treatment Agent:Temozolomide; XL184
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of XL184 that can be given in combination with temozolomide and radiation
therapy to patients with anaplastic glioma or glioblastoma. The safety of this
combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Brain; CNS
Phase of Study:Phase I
Treatment Agents:Temozolomide
XL184
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Exelixis
Return Visit:Every 4 weeks
Home Care:Patients will take XL-184 and temozolomide at home


Hide details for Study Contact InformationStudy Contact Information

Physician Name:John DeGroot
Dept:Neuro Oncology
For Clinical Trial Enrollment:713-792-2883
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults